Mechanistically, anidulafungin reactivated anti-tumor immunity by blocking the PD-1/PD-L1 interaction, thereby mimicking the immune checkpoint blockade achieved by monoclonal antibodies. The gene discussed is PDCD1; the disease is neoplasm.